Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,246 across all filing types
Latest filing 2020-06-08 Board/Management Inform…
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
BLISS GVS PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/06/2020 ,inter alia, to consider and approve the Audited Standalone and ....
Board/Management Information Classification · 95% confidence The document is an official communication from Bliss GVS Pharma Ltd. addressed to stock exchanges, informing them about an upcoming Board Meeting scheduled for June 16, 2020. The purpose of the meeting includes considering the audited standalone and consolidated financial statements and results for the quarter and financial year ended March 31, 2020, and recommending a dividend. The document references regulatory compliance under SEBI regulations and mentions the closure of the trading window due to insider trading rules. The document is a notice of a board meeting rather than the financial results or report itself. It does not contain actual financial data or detailed financial analysis but is an announcement of an event where such reports will be considered. Therefore, it fits the category of Board/Management Information (MANG), which covers announcements of board meetings and related management information.
2020-06-08 English
Resignation
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the resignation of a Non-Executive Director, Mr. Gautam Ashra, from the company Bliss GVS Pharma Ltd. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosure of events or information. The content focuses solely on the announcement of a change in the company's board of directors, providing details about the resignation and effective date. There are no financial statements, management discussion, or other report contents. The document is not a full report but an announcement of a board/management change. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (5590 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2020-06-08 English
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Para A of part A of schedule III to the ....
Regulatory Filings
2020-06-08 English
Please find enclosed herewith the half yearly compliance certificate issued by Company Secretary in Practice as per Regulation 40(9) of the Securities and Exchange Board of India (Listing ....
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 40(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended March 31, 2020. It is a compliance certificate from a Company Secretary in Practice regarding share transfer and related activities. The document does not contain financial statements or detailed financial data, nor is it an announcement of a report publication. It is a regulatory compliance certificate related to share transfer processes, which fits best under Regulatory Filings (RNS) as it is a formal regulatory submission but not a financial report or other specific filing type.
2020-05-26 English
Updates
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2020. It is a confirmation from the Registrar and Share Transfer Agent regarding securities dematerialized/rematerialized during the quarter. The document is a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements or detailed financial data. It is also not an announcement of voting results, management changes, or capital changes. Given the nature of the document as a regulatory certificate related to securities and depository compliance, it fits best under Regulatory Filings (RNS). The document length (9360 characters) and content confirm it is not a brief announcement but a formal certificate. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-05-15 English
Please find enclosed herewith a certificate received from Universal Capital Securities Private Limited, Registrar and Share Transfer Agent of the Company under Regulation 74(5) of the Securities ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchanges (National Stock Exchange of India and BSE Limited) regarding a certificate received from the company's Registrar and Share Transfer Agent under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2020. The content suggests it is a regulatory compliance filing related to shareholding or transfer agent certification rather than a full financial report or announcement of voting results, management changes, or capital updates. The document length is 15,000 characters, indicating it is not a brief announcement but a formal regulatory filing. There is no indication of financial statements, audit reports, or earnings data. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.